Arrowhead Research | ARWR - Assets


Arrowhead Research reported $1.6B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Anika Therapeutics USD 190.27M 833K Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xencor USD 875.5M 6.68M Dec/2025